Skip to main content
Premium Trial:

Request an Annual Quote

Quark Receives Japanese Patent on Proprietary Gene Target

Premium

Quark Pharmaceuticals announced this week that it has received a Japanese patent covering a proprietary gene target.

The patent, No. 4354633, is entitled "Hypoxia-Regulated Genes," and claims various aspects of the RTP801 gene, including inhibitors targeting either the mRNA or peptide products of the gene, Quark said.

The intellectual property is part of an estate covering Quark's ocular disease drug RTP801i-14, which was licensed to Pfizer and is currently in clinical testing as a treatment for wet age-related macular degeneration and diabetic macular edema (see RNAi News, 9/28/2006).

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.